Theramex company information, Employees & Contact Information

UK marketing watchdog slams Theramex for 'wholly unacceptable' compliance failings Fierce Pharma

Daré Bioscience and Theramex Announce Co-Development and GlobeNewswire

Linzagolix▼ – A Flexible Treatment Option for Women with Uterine Fibroids European Medical Journal

NHS patients to access Theramex’s endometriosis pill following NICE recommendation PMLiVE

Radius Pharmaceuticals Expands Abaloparatide Licensing Agreement with Theramex Granting Additional Commercialization Rights Including Mexico, Canada, South Africa, Israel, and Russia ACCESS Newswire

Theramex Announces Agreement to Acquire the European Rights to Duphaston® and Femoston® From Viatris, Inc. Business Wire

Theramex Ganirelix News-Medical

UK watchdog fines Viatris $1.9 mln over rule breach in Theramex probe Reuters

NICE supports Theramex’s Eladynos for post-menopause osteoporosis Pharmaceutical Technology

CVC Fund VI agrees exit of Theramex cvc.com

Latham Advises on CVC’s Sale of Theramex to PAI Partners and Carlyle Latham & Watkins LLP

Carlyle, PAI Agree to Buy CVC’s Women’s Health Business Theramex Bloomberg

International Women's Day sees Theramex reinforce its commitment to women's health International Women's Day

Theramex receives recommendation for YSELTY in Scotland Pharmafile

Theramex The Pharma Letter

PE Today: CVC Exits Theramex, Estancia Invests in Financial Services Middle Market Growth

Theramex's uterine fibroid drug Yselty backed for NHS use pharmaphorum

Theramex launches Bijuva® / Bijuve® (estradiol and progesterone), the first and only body-identical combined hormone therapy treatment for post-menopausal women* Business Wire

ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix GlobeNewswire

Carlyle, PAI Nearing $1.4 Billion Deal for CVC’s Theramex Bloomberg

Theramex’s Eladynos recommended by NICE for post-menopausal bone disease PharmaTimes

Theramex enters into an exclusive licensing agreement with Radius Health Inc to commercialise ELADYNOS® Taylor Wessing

IQWiG Finds "Not Proven" Added Benefit for Theramex’s Yselty in Endometriosis, Citing Persistent Lack of Comparative Data Under AMNOG NAVLIN DAILY

With approval in sight, ObsEva sells regional rights to women's health drug for tiny upfront Fierce Biotech

Theramex Enters Into an Exclusive Licensing Agreement With Radius Health Inc, to Commercialise ELADYNOS ® ▼ in the European Economic Area, the United Kingdom, Australia and Brazil Via TT

Theramex gains European rights to Duphaston and Femoston from Viatris Pharmaceutical Technology

Theramex to market Prolia biosimilar in Europe and Australia Generics and Biosimilars Initiative

Carlyle and PAI Partners to acquire Theramex from CVC Funds The Pharma Letter

Working your way up in women’s health Pf Media

Theramex wins decentralized procedure approval in EU, UK for hormone drug Drug Delivery Business

Theramex And Alkem’s Enzene Ally On Denosumab Citeline News & Insights

Theramex to buy ex-US rights of BIJUVA and IMVEXXY from TherapeuticsMD Pharmaceutical Business review -

Theramex launches osteoporosis drug Livogiva in Europe Pharmafile

Pharma deal could reduce choice and lead to higher prices for HRT treatments GOV.UK

Theramex joins levloan pipeline GlobalCapital

Theramex Launches Non-hormonal Femarelle® on the 12th of May NTB Kommunikasjon

Theramex Enters the OTC Market with Femarelle, a Non-hormonal Option to Treat Menopause Symptoms Femtech Insider

Theramex Buys Janssen’s Evorel Amid Ongoing HRT Shortages Citeline News & Insights

Real world evidence demonstrates that risedronate GR (Actonel® GR) has superior outcomes for fracture risk reduction in patients with osteoporosis compared to immediate release oral bisphosphonates NTB Kommunikasjon

Alert: Evorel Sequi Dispensing Doctors' Association

Private equity giants snap up women’s health firm Theramex for £1.2bn City AM

Theramex launches first body-identical combined hormone therapy treatment Pf Media

Vivian announces representation of global women’s health giant Theramex The Malta Independent

Theramex Launches Antadys In France The Pharma Letter